TY -的T1 -分析的追踪损失4099 multidrug-resistant pulmonary tuberculosis patients JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.00353-2018 VL - 54 IS - 1 SP - 1800353 AU - Walker, Ian F. AU - Shi, Oumin AU - Hicks, Joseph P. AU - Elsey, Helen AU - Wei, Xiaolin AU - Menzies, Dick AU - Lan, Zhiyi AU - Falzon, Dennis AU - Migliori, Giovanni Battista AU - Pérez-Guzmán, Carlos AU - Vargas, Mario H. AU - García-García, Lourdes AU - Sifuentes Osornio, José AU - Ponce-De-León, Alfredo AU - van der Walt, Martie AU - Newell, James N. Y1 - 2019/07/01 UR - //www.qdcxjkg.com/content/54/1/1800353.abstract N2 - Loss to follow-up (LFU) of ≥2 consecutive months contributes to the poor levels of treatment success in multidrug-resistant tuberculosis (MDR-TB) reported by TB programmes. We explored the timing of when LFU occurs by month of MDR-TB treatment and identified patient-level risk factors associated with LFU.We analysed a dataset of individual MDR-TB patient data (4099 patients from 22 countries). We used Kaplan–Meier survival curves to plot time to LFU and a Cox proportional hazards model to explore the association of potential risk factors with LFU.Around one-sixth (n=702) of patients were recorded as LFU. Median (interquartile range) time to LFU was 7 (3–11) months. The majority of LFU occurred in the initial phase of treatment (75% in the first 11 months). Major risk factors associated with LFU were: age 36–50 years (HR 1.3, 95% CI 1.0–1.6; p=0.04) compared with age 0–25 years, being HIV positive (HR 1.8, 95% CI 1.2–2.7; p<0.01) compared with HIV negative, on an individualised treatment regimen (HR 0.7, 95% CI 0.6–1.0; p=0.03) compared with a standardised regimen and a recorded serious adverse event (HR 0.5, 95% CI 0.4–0.6; p<0.01) compared with no serious adverse event.Both patient- and regimen-related factors were associated with LFU, which may guide interventions to improve treatment adherence, particularly in the first 11 months.Globally, 75% of loss to follow-up occurs in the first 11 months of MDR-TB treatment. Highest risk is HIV positive, age 36–50 years and standardised regimen. http://bit.ly/2GwKcS1 ER -